AUTHORS
Manisha Bhutani, MD, Joni Evans2, Rebecca Metellus3, Myra Robinson4, Sharvil Desai5, Amresh Hanchate6, Peter M Voorhees, MD7, Shelley Anne Jazowski, PhD, MPH8
AFFILIATIONS
1 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
2 Wake Forest University School of Medicine, Winston-Salem, United States
3 Geisinger Commonwealth School of Medicine, Scranton, United States
4 Atrium Health Levine Cancer Institute, Charlotte, United States
5 Atrium Health Levine Cancer Institute, Charlotte, United States
6 Wake Forest University School of Medicine, Winston-Salem, United States
7 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, United States
8 Wake Forest University School of Medicine, Winston-Salem, United States
ABSTRACT
Introduction: Racial and ethnic disparities in multiple myeloma (MM) treatment use and subsequent clinical outcomes are well-documented. However, prior SEER-Medicare studies largely predate the adoption of anti-CD38 monoclonal antibodies and next-generation proteasome inhibitors. Whether disparities extend to these treatments, and whether treatment gaps contribute to survival differences among older adults, remains unclear. We assessed racial and ethnic disparities in receipt of antimyeloma treatment and autologous stem cell transplant (ASCT), and survival among traditional Medicare beneficiaries with MM.
Methods: Using the SEER-Medicare linked database, we identified White, Black, and Hispanic beneficiaries diagnosed with MM from 2010 to 2019. We identified receipt of ASCT and antimyeloma treatment (immunomodulatory agents, proteasome inhibitors, anti-CD38 monoclonal antibodies) from diagnosis until disenrollment, death, or December 31, 2020. Modified Poisson regression and Cox proportional hazards models assessed the likelihood of and time to receiving ASCT and antimyeloma treatment; Cox models also examined time to all-cause mortality among the entire cohort and separately among those who did and did not receive ASCT and antimyeloma treatment. Consistent with the National Academy of Medicine's definition of racial and ethnic disparities, primary models adjusted only for beneficiaries' health status (age, sex, comorbidities, and year of diagnosis). Since social determinants of health have been associated with disparities in anticancer treatment access, in secondary analyses, we stratified treatment and ASCT models by race and ethnicity and adjusted for socioeconomic status and urbanicity.
Results: Among 13,994 eligible beneficiaries, 75.9% were White, 14.8% were Black, and 9.4% were Hispanic. In unadjusted analyses, receipt of ASCT and antimyeloma treatment was lower among Black (6.4% and 61.6%) and Hispanic beneficiaries (7.2% and 68.1%) relative to their White counterparts (11.1% and 70.8%). Among those treated, White beneficiaries had the highest rates of using lenalidomide (57.0% versus 46.8% [Black] and 51.3% [Hispanic]), daratumumab (14.3% versus 9.4% and 9.6%), and carfilzomib (12.6% versus 8.9% and 10.1%). In adjusted models, Black beneficiaries had a lower likelihood than White beneficiaries of receiving ASCT (adjusted risk ratio [aRR] 0.53, 95% CI 0.45-0.63) and antimyeloma treatment (aRR 0.86, 95% CI 0.83-0.89). Compared with White beneficiaries, Hispanic beneficiaries had a 38% lower likelihood of receiving ASCT (aRR 0.62, 95% CI 0.51-0.76). Time-to-treatment analyses yielded similar disparities.
Racial and ethnic treatment disparities were accompanied by worse survival. Black and Hispanic beneficiaries had lower median overall survival (37.1 and 37.0 months) relative to White beneficiaries (43.4 months). In adjusted models, Black (adjusted hazard ratio [aHR] 1.22, 95% CI 1.15-1.30) and Hispanic beneficiaries (aHR 1.14, 95% CI 1.06-1.22) had higher all-cause mortality compared with White beneficiaries. Disparities persisted among treated beneficiaries: Black beneficiaries receiving antimyeloma treatment or ASCT had worse survival than their White counterparts (aHR 1.22, 95% CI 1.13-1.32 and aHR 1.42, 95% CI 1.05-1.92, respectively). Findings were similar for treated Hispanic beneficiaries (aHR 1.21, 95% CI 1.10-1.32), although the association among those receiving ASCT did not reach statistical significance (aHR 1.18, 95% CI 0.79-1.76).
In secondary analyses, receipt of Medicare Part D low-income subsidies was negatively associated with likelihood of and time to receiving antimyeloma treatment and ASCT across all racial and ethnic groups. Across all racial and ethnic groups, rurality was not associated with the likelihood of or time to receiving treatment and ASCT.
Conclusions: Among traditional Medicare beneficiaries with MM, Black and Hispanic beneficiaries had lower rates of ASCT and antimyeloma therapy, including lenalidomide, daratumumab, and carfilzomib. Survival disparities persisted despite treatment, suggesting that differences in treatment intensity, regimen selection, or supportive care contribute to inferior outcomes. Receipt of Part D low-income subsidies was associated with lower treatment rates across groups, identifying a modifiable policy target, whereas rurality was not. Interventions addressing both access and treatment quality are needed to achieve equitable MM outcomes.
DISCLOSURES
Manisha Bhutani, MD: Johnson & Johnson - Research Funding; Takeda - Research Funding; Abbvie - Research Funding; Caribou Biosciences - Research Funding; The Binding Site - Research Funding; Celgene - Research Funding; Amgen - Research Funding; Bristol Myers Squibb - Research Funding; Caribou Biosciences - Consultancy (Includes expert testimony)